| __timestamp | Ionis Pharmaceuticals, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 241751000 | 3243000 |
| Thursday, January 1, 2015 | 322292000 | 2472000 |
| Friday, January 1, 2016 | 344320000 | 2548000 |
| Sunday, January 1, 2017 | 374644000 | 19623000 |
| Monday, January 1, 2018 | 1820000 | 30421000 |
| Tuesday, January 1, 2019 | 4000000 | 32793999 |
| Wednesday, January 1, 2020 | 12000000 | 28304000 |
| Friday, January 1, 2021 | 11000000 | 620000 |
| Saturday, January 1, 2022 | 14000000 | 755000 |
| Sunday, January 1, 2023 | 9133000 | 1322000 |
| Monday, January 1, 2024 | 11215000 |
Igniting the spark of knowledge
In the ever-evolving landscape of biotechnology, understanding cost structures is crucial. Ionis Pharmaceuticals, Inc. and Viridian Therapeutics, Inc. have shown intriguing trends in their cost of revenue from 2014 to 2023. Ionis Pharmaceuticals experienced a significant peak in 2017, with costs reaching nearly 375% of their 2014 levels. However, by 2023, their costs had decreased by approximately 96% from this peak, indicating a strategic shift or operational efficiency.
Conversely, Viridian Therapeutics saw a dramatic rise in costs in 2018, with a staggering increase of over 900% compared to 2014. This surge was followed by a gradual decline, with 2023 costs being about 60% lower than their 2018 peak. These trends highlight the dynamic nature of cost management in the biotech sector, reflecting both companies' adaptive strategies in response to market demands and operational challenges.
Comparing Cost of Revenue Efficiency: Eli Lilly and Company vs Ionis Pharmaceuticals, Inc.
AstraZeneca PLC vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Ionis Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Dr. Reddy's Laboratories Limited and Ionis Pharmaceuticals, Inc.
Cost of Revenue Comparison: Exelixis, Inc. vs Viridian Therapeutics, Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Viridian Therapeutics, Inc.'s Expenses
Cost Insights: Breaking Down Telix Pharmaceuticals Limited and Ionis Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Ionis Pharmaceuticals, Inc. vs CRISPR Therapeutics AG
Cost of Revenue Trends: Ionis Pharmaceuticals, Inc. vs PTC Therapeutics, Inc.
Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Cost Insights: Breaking Down Taro Pharmaceutical Industries Ltd. and Viridian Therapeutics, Inc.'s Expenses
Cost of Revenue Comparison: Viridian Therapeutics, Inc. vs MiMedx Group, Inc.